echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The generic drugs of rituximab and Herceptin are about to land in Europe

    The generic drugs of rituximab and Herceptin are about to land in Europe

    • Last Update: 2017-02-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: DXY in Europe, patients' burden may be greatly reduced when they need to use rituximab and Herceptin for treatment, because the generic drugs of these two drugs will be on the market soon There are signs that the European regulatory agency, the European Drug Administration (EMA), is about to approve the South Korean made rituximab biosimilars celltrion NAPP pharmaceutical will sell the intravenous drug in the UK "We expect to launch products in the near future," said Roberts of the company "EMA did not respond to the upcoming approval, but its website shows that the agency is evaluating two biosimilars of rituximab and three biosimilars of Herceptin Industry analysts believe mylan and its partner biocon could become the first European company to receive approval for a Herceptin biosimilars by the end of this year High sales figures are dangerous Rituximab sold $7.3 billion worldwide last year, while Herceptin brought $6.75 billion Although their generic drugs are sold in parts of Asia, Europe is the first big market, and the U.S generic drugs are still a long way from being listed Roche admitted this month that it will see competition from biosimilars this year, but hopes to offset that disadvantage with more efficient and convenient follow-up products Investors have been concerned about how doctors can quickly trust new drugs, while cancer experts and health service providers are worried about the financial situation of the European health care system, saying they plan to use drugs at reduced prices Oncologists believe that savings have created the conditions for new and more expensive immunotherapy drugs, which are revolutionary, but can cost more than $100000 per patient Tabernero, director of medical oncology at Vall d'Hebron University Hospital in Barcelona, said: "whether in public or private medical institutions, we need to provide sustainable health care and bio imitations, which is obviously a good way to improve affordability Tabernero believes that biomimetic rheumatoid arthritis drugs (anti TNF, launched in Europe a few years ago) will have the same effect Although it took doctors several months to gradually recognize the first biomimetic antibody, the demand has declined since then, and product competition has greatly reduced the price of anti TNF Since biotech drugs are made from living cells, it is impossible to make accurate imitations like simple pharmaceutical preparations, so regulators pay extra attention to the approval of drugs with very "similar" effects This makes the development cost of biopharmaceuticals relatively high, resulting in little initial price discount However, biosimilars' anti TNFs are now selling at a discount of about 50%, with Sandoz, one of the largest biosimilars companies, potentially offering as much as 75% in some cases Tabernero, President of the European Society of medical oncology, CO authored a technical paper last month that presented the case of biosimilars, saying he would "like to see a 40-60% discount." Depending on the rheumatic sector, the initial discount may be around 30% "If European oncologists can offer highly efficient biosimilars at a better price, I believe they will be very actively accepted," said workman, chief executive of Cancer Research UK "Officials from European national health systems are also paying close attention to this Nordic countries and Germany are leading in the use of biosimilars, but other countries are taking action to promote the use of biosimilars For example, the UK has spent more than 300 million pounds ($375 million) on rituximab and Herceptin, and has set a goal of giving 90% of new patients in NHS hospitals access to future biosimilars The British Association of oncology announced last week that it will work to optimize the use of biomimetic antibodies in cancer treatment At least initially, new cancer patients, rather than those who have already started using existing drugs, will be the most likely recipients of biosimilars However, since the nature of treatment usually involves multiple treatment options, this means that it may not prevent the acceptance of biosimilars in the medium term "We won't see rapid acceptance in every area, but we still want to see faster acceptance than we used to use bio generics," said Roberts of NAPP EMA has so far approved 23 biosimilars, compared with only four in the United States "EMA has done a good job, it realized many years ago that it is very strategic to manage the cost of drugs in Europe, they have developed clear and easy to understand guidelines very early," said kubli of Bellevue asset management in Zurich Kubli believes that sales of biosimilars will continue to surge in the next few years, even if the price discount is as low as 50% to 70%, as patents for a large number of biotech drugs continue to expire until 2022.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.